2020
DOI: 10.1016/j.gde.2020.01.002
|View full text |Cite
|
Sign up to set email alerts
|

Telomere maintenance mechanisms in cancer: telomerase, ALT or lack thereof

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
34
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
6
1
1

Relationship

1
7

Authors

Journals

citations
Cited by 31 publications
(35 citation statements)
references
References 58 publications
1
34
0
Order By: Relevance
“…Two distinct pathways have been discovered so far that ensure telomere maintenance in indefinitely dividing cancer cells: either telomerase reactivation or activation of an ALTernative mechanism of telomere maintenance. An accumulating body of evidence suggests that these two pathways are mutually exclusive and cannot co-exist in the same cell, at least under the physiological conditions of telomerase expression (Claude & Decottignies, 2020).…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Two distinct pathways have been discovered so far that ensure telomere maintenance in indefinitely dividing cancer cells: either telomerase reactivation or activation of an ALTernative mechanism of telomere maintenance. An accumulating body of evidence suggests that these two pathways are mutually exclusive and cannot co-exist in the same cell, at least under the physiological conditions of telomerase expression (Claude & Decottignies, 2020).…”
Section: Discussionmentioning
confidence: 99%
“…Cancer cells circumvent entry into senescence and attain immortality by maintaining their telomere length via one of two, mutually exclusive, TMMs: (i) reactivation of the hTERT gene encoding the catalytic subunit of telomerase (TEL + cells) or (ii) hijacking a subset of cellular DNA replication and repair factors to perform "alternative lengthening of telomeres" (ALT + cells) (Shay & Wright, 2005;Cesare & Reddel, 2010). While 80-85% of cancer cells rely on telomerase activity, an estimated 10% of cancers use the ALT mechanism and its frequency may reach up to 20% in pediatric cancers (Shay & Bacchetti, 1997;Heaphy et al, 2011;Claude & Decottignies, 2020).…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Nevertheless, our finding that genome-wide 5hmC and R-loops overlap more robustly at the transcription termination site of active genes supports a model whereby TET enzymes act upstream of R-loop formation during transcription termination 34 . Telomeres, the nucleoprotein complexes found at the ends of linear eukaryotic chromosomes, can be maintained in proliferating ES and cancer cells by either the activity of telomerase or the alternative lengthening of telomeres (ALT) pathway 35 . ALT telomeres are maintained by mechanisms relying on homologous recombination (HR) between telomeric repeats.…”
Section: Discussionmentioning
confidence: 99%
“…Certain tumour types seem to utilize ALT more frequently. Especially, in tumours originating from mesenchymal tissues, such as sarcomas, the ALT phenotype is overrepresented 7‐9 . Sarcomas are a heterogeneous cancer group and ALT status has been demonstrated as negative prognostic factor in some sarcoma subtypes 22‐25 .…”
Section: Introductionmentioning
confidence: 99%